ID   Karpas-620
AC   CVCL_1823
SY   KARPAS-620; Karpas 620; KARPAS 620; Karpas620; KARPAS620; K620
DR   EFO; EFO_0006449
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-1088
DR   BioSample; SAMN03473162
DR   BioSample; SAMN10989552
DR   Cell_Model_Passport; SIDM01006
DR   Cosmic; 720777
DR   Cosmic; 2081387
DR   Cosmic; 2131564
DR   Cosmic; 2367275
DR   Cosmic; 2809762
DR   Cosmic-CLP; 1327775
DR   DepMap; ACH-000193
DR   DSMZ; ACC-514
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 1327775
DR   GEO; GSM887196
DR   GEO; GSM888269
DR   GEO; GSM1374589
DR   GEO; GSM1669978
DR   IARC_TP53; 28386
DR   LiGeA; CCLE_349
DR   LINCS_LDP; LCL-2053
DR   PharmacoDB; KARPAS620_732_2019
DR   Progenetix; CVCL_1823
DR   Wikidata; Q54899502
DR   Ximbio; 152425
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2310698;
RX   PubMed=10936422;
RX   PubMed=11157491;
RX   PubMed=16956823;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=19064000;
RX   PubMed=21173094;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25688540;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30545397;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Characteristics: Produces IgG kappa.
CC   HLA typing: A*02:01; B*44; C*05:01 (Direct_author_submission).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=11157491; PubMed=21173094; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Homozygous (PubMed=21173094; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.6%; Native American=0%; East Asian, North=2.67%; East Asian, South=0%; South Asian=0%; European, North=63.77%; European, South=31.96% (PubMed=30894373).
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
CC   Discontinued: DSMZ; ACC-514; true.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,14
ST   D16S539: 11,12
ST   D18S51: 13,18
ST   D21S11: 29,31.2
ST   D3S1358: 14,16
ST   D5S818: 9,11
ST   D7S820: 9
ST   D8S1179: 10,15
ST   FGA: 26
ST   Penta D: 10,13
ST   Penta E: 14,15
ST   TH01: 6,7
ST   TPOX: 11,12
ST   vWA: 17,19
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 31
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2310698; DOI=10.1111/j.1365-2141.1990.tb02540.x;
RA   Nacheva E., Fischer P.E., Sherrington P.D., Labastide W., Lawlor E.,
RA   Conneally E., Blaney C., Hayhoe F.G.J., Karpas A.;
RT   "A new human plasma cell line, Karpas 620, with translocations
RT   involving chromosomes 1, 11 and 14.";
RL   Br. J. Haematol. 74:70-76(1990).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=16956823;
RA   Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L.,
RA   Moreau P., Amiot M., Pellat-Deceunynck C.;
RT   "The phenotype of normal, reactive and malignant plasma cells.
RT   Identification of 'many and multiple myelomas' and of new targets for
RT   myeloma therapy.";
RL   Haematologica 91:1234-1240(2006).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=19064000; DOI=10.1016/j.dnarep.2008.11.010;
RA   Dib A., Glebov O.K., Shou Y.-P., Singer R.H., Kuehl W.M.;
RT   "A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line
RT   expresses only cyclin D1: yet both cyclin D1 and MYC are repositioned
RT   in close proximity to the 3'IGH enhancer.";
RL   DNA Repair 8:330-335(2009).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456;
RA   Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30545397; DOI=10.1186/s13045-018-0679-0;
RA   Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S.,
RA   Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "Whole-exon sequencing of human myeloma cell lines shows mutations
RT   related to myeloma patients at relapse with major hits in the DNA
RT   regulation and repair pathways.";
RL   J. Hematol. Oncol. 11:137.1-137.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//